Mark Rubino, MD
Neurology · Naples, FLNPI 1285605469
Payments from drug & device makers
Across 252 payments — averaging $35.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Biogen$708
- Teva Pharmaceuticals USA, Inc.$574
- Amgen$443
- Lilly USA, LLC$418
- Eisai Inc.$222
- plus $1K from 29 others
What the payments were for
- Speaking & faculty fees$4,10046%
- Travel & lodging$200%
- Food & beverage$4,68952%
- Education$1321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $5,136 |
| Biogen | 31 | $708 |
| Teva Pharmaceuticals USA, Inc. | 30 | $574 |
| Amgen | 21 | $443 |
| Lilly USA, LLC | 21 | $418 |
| Eisai Inc. | 7 | $222 |
| Lundbeck LLC | 8 | $169 |
| Upsher-smith Laboratories LLC | 11 | $149 |
| Mallinckrodt Hospital Products Inc. | 1 | $125 |
| Novartis | 6 | $114 |
| Sanofi | 2 | $111 |
| AstraZeneca | 1 | $99 |
| Johnson & Johnson | 3 | $75 |
| EMD Serono, Inc. | 4 | $61 |
| Bristol Myers Squibb | 3 | $48 |
| Supernus Pharmaceuticals, Inc. | 3 | $45 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| Pfizer | 2 | $40 |
| Daiichi Sankyo Inc. | 2 | $40 |
| SK Life Science, Inc. | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Gilead | 1 | $25 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Tanabe Pharma America, Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Abbott | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Promius Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,941 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 15 | $150,166 |
| Xtampza ErOxycodone Myristate | 83 | $94,944 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 367 | $15,441 |
| MovantikNaloxegol Oxalate | 23 | $14,250 |
| Oxycodone Hcl | 450 | $11,651 |
| Keppra XrLevetiracetam | 12 | $11,036 |
| VimpatLacosamide | 11 | $10,937 |
| Morphine Sulfate ErMorphine Sulfate | 207 | $8,535 |
| Hysingla ErHydrocodone Bitartrate | 12 | $8,395 |
| Fentanyl | 52 | $7,656 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 143 | $5,812 |
| Gabapentin | 216 | $4,443 |
| Rivastigmine | 26 | $3,944 |
| Methadone Hcl | 77 | $2,844 |
| Ondansetron OdtOndansetron | 18 | $2,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $708 | $150,16615 claims |
| Redhill Biopharma Inc.Movantik | $15 | $14,25023 claims |
| Upsher-smith Laboratories LLCTopiramate | $149 | $792100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,434 neurology providers in Florida.
Other neurology in Naples
- William JustizNaples$6.1M
- Matthew BakerNaples$5.4M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.